EMPULSE Response Predictor (Empagliflozin in Heart Failure)

Clinical calculation support · Verify results before clinical use

Patient profile

Enter baseline clinical characteristics to calculate the original exploratory index.

—Score

Patient age at assessment.

The original tool groups all LVEF >40% together.

Use clinical assessment; the original tool does not define operational criteria.

Reset form

Clinical context

EMPULSE was a randomized, double-blind trial of empagliflozin 10 mg once daily versus placebo in 530 patients hospitalized with acute de novo or decompensated chronic heart failure. Treatment was started after clinical stabilization (median 3 days after admission), with follow-up to 90 days.

The primary endpoint was a hierarchical clinical-benefit composite comprising all-cause death, heart-failure events and change in Kansas City Cardiomyopathy Questionnaire Total Symptom Score. The trial reported a stratified win ratio of 1.36 (95% CI 1.09–1.68; P=0.0054) favoring empagliflozin.

What this tool does—and does not do

  • Applies the original uploaded code's heuristic point assignments to the entered values.
  • Displays its derived index only as an exploratory arithmetic output.
  • Does not reproduce the trial's win-ratio analysis or estimate a validated patient-level treatment effect.
  • Does not replace assessment of clinical stability, contraindications, renal function, volume status, or clinician judgment.

Clinical evidence

Voors AA, Angermann CE, Teerlink JR, et al.The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nature Medicine. 2022;28:568–574. doi:10.1038/s41591-021-01659-1
ClinicalTrials.govEMPULSE study registration, NCT04157751. Official trial record
Disclaimer: This page is an educational tool, not a validated clinical prediction rule. The original scoring weights and 5–95 index conversion are not established by the EMPULSE randomized trial publication. The trial's average treatment effect should not be converted into an individual probability using this score. Use current prescribing information and local guidance, and assess clinical stability and patient-specific risks before treatment.